Cargando…

Sodium glucose co-transporter inhibitors – A new class of old drugs

Sodium glucose co-transporter (SGLT) inhibitors are a new class of drugs which are used in the pharmacotherapy of Type-II diabetes, which happens to be a major risk factor for developing both micro as well as macro-vascular complications. These drugs inhibit the glucose reabsorption by inhibiting SG...

Descripción completa

Detalles Bibliográficos
Autores principales: Malhotra, Aneeta, Kudyar, Surbhi, Gupta, Anil K., Kudyar, Rattan P., Malhotra, Pavan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606572/
https://www.ncbi.nlm.nih.gov/pubmed/26539362
http://dx.doi.org/10.4103/2229-516X.165363
_version_ 1782395376460890112
author Malhotra, Aneeta
Kudyar, Surbhi
Gupta, Anil K.
Kudyar, Rattan P.
Malhotra, Pavan
author_facet Malhotra, Aneeta
Kudyar, Surbhi
Gupta, Anil K.
Kudyar, Rattan P.
Malhotra, Pavan
author_sort Malhotra, Aneeta
collection PubMed
description Sodium glucose co-transporter (SGLT) inhibitors are a new class of drugs which are used in the pharmacotherapy of Type-II diabetes, which happens to be a major risk factor for developing both micro as well as macro-vascular complications. These drugs inhibit the glucose reabsorption by inhibiting SGLT, which exhibits a novel and promising mechanism of action by promoting the urinary glucose excretion hence providing a basis of therapeutic intervention. Results of SGLT-II inhibitors are very encouraging as there is a significant elevation of GLP-1 level, which forms the basis of relevance in treatment of diabetes. It targets the HbA1C and keeps a check on its levels. It also exerts other positive benefits such as weight loss, reduction in blood glucose levels, reduction in blood pressure and improvement in insulin resistance and β-cell dysfunction: All contributing to effective glycemic control. SGLT inhibition will develop as effective modality as it has the capability of inhibiting reabsorption of greater percentage of filtered glucose load.
format Online
Article
Text
id pubmed-4606572
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-46065722015-11-04 Sodium glucose co-transporter inhibitors – A new class of old drugs Malhotra, Aneeta Kudyar, Surbhi Gupta, Anil K. Kudyar, Rattan P. Malhotra, Pavan Int J Appl Basic Med Res Educational Forum Sodium glucose co-transporter (SGLT) inhibitors are a new class of drugs which are used in the pharmacotherapy of Type-II diabetes, which happens to be a major risk factor for developing both micro as well as macro-vascular complications. These drugs inhibit the glucose reabsorption by inhibiting SGLT, which exhibits a novel and promising mechanism of action by promoting the urinary glucose excretion hence providing a basis of therapeutic intervention. Results of SGLT-II inhibitors are very encouraging as there is a significant elevation of GLP-1 level, which forms the basis of relevance in treatment of diabetes. It targets the HbA1C and keeps a check on its levels. It also exerts other positive benefits such as weight loss, reduction in blood glucose levels, reduction in blood pressure and improvement in insulin resistance and β-cell dysfunction: All contributing to effective glycemic control. SGLT inhibition will develop as effective modality as it has the capability of inhibiting reabsorption of greater percentage of filtered glucose load. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4606572/ /pubmed/26539362 http://dx.doi.org/10.4103/2229-516X.165363 Text en Copyright: © 2015 International Journal of Applied and Basic Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Educational Forum
Malhotra, Aneeta
Kudyar, Surbhi
Gupta, Anil K.
Kudyar, Rattan P.
Malhotra, Pavan
Sodium glucose co-transporter inhibitors – A new class of old drugs
title Sodium glucose co-transporter inhibitors – A new class of old drugs
title_full Sodium glucose co-transporter inhibitors – A new class of old drugs
title_fullStr Sodium glucose co-transporter inhibitors – A new class of old drugs
title_full_unstemmed Sodium glucose co-transporter inhibitors – A new class of old drugs
title_short Sodium glucose co-transporter inhibitors – A new class of old drugs
title_sort sodium glucose co-transporter inhibitors – a new class of old drugs
topic Educational Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606572/
https://www.ncbi.nlm.nih.gov/pubmed/26539362
http://dx.doi.org/10.4103/2229-516X.165363
work_keys_str_mv AT malhotraaneeta sodiumglucosecotransporterinhibitorsanewclassofolddrugs
AT kudyarsurbhi sodiumglucosecotransporterinhibitorsanewclassofolddrugs
AT guptaanilk sodiumglucosecotransporterinhibitorsanewclassofolddrugs
AT kudyarrattanp sodiumglucosecotransporterinhibitorsanewclassofolddrugs
AT malhotrapavan sodiumglucosecotransporterinhibitorsanewclassofolddrugs